By Colin Kellaher
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
The Boston clinical-stage company said the Phase 2b study didn't meet statistical significance thresholds for its primary endpoint of change in a measure of the disease or any of its key secondary endpoints.
CervoMed said it is pausing all preparations for a planned Phase 3 study until it completes a full analysis of the Phase 2b study results.
Trading in shares of CervoMed, which closed Monday at $10.25, was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2024 07:21 ET (12:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。